Scientific Program
The entire program will be presented at the New York Academy of Medicine, therefore the time schedule below is Eastern Standard Time (EST).
Click on the button below to download the Final Program:
FINAL PROGRAM
| WEDNESDAY, NOVEMBER 3, 2021 |
| 01.00 pm | Registration opens |
| 01.00 pm – 04.00 pm | Poster Viewing |
| Opening
Chairs Opening Session: |
|
| 04.00 pm – 04.10 pm | Welcome address |
| 04.10 pm – 04.35 pm | Setting the stage – Historic perspectives Georg Stingl (Vienna, Austria) |
| 04.35 pm – 05.00 pm | Setting the stage – The translational revolution in inflammatory skin diseases James G. Krueger (New York, NY, USA) |
| 05.00 pm – 05.30 pm | Keynote lecture: Autoinflammatory diseases Dan Kastner (Bethesda, MD, USA) |
| 05.30 pm – 06.30 pm | Chairs Afternoon Session: Joel Gelfand (Philadelphia, PA, USA) Sonja Ständer (Münster, Germany) Oral presentations from selected abstracts (non-CME) Treatment of sarcoidosis with cutaneous involvement with tofacitinib: results of an open-label clinical trial with mechanistic insight Extensive Lymphocyte Clonal Expansion and Formation of Tertiary Lymphoid Structure in Hidradenitis Suppurativa RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis Vitiligo Patients Show Significant Changes in Skin and Blood Immune/Melanocytes Biomarkers with Oral JAK3/TEC Inhibitor Ritlecitinib Efficacy and Safety Results of a Randomized, Double-blind, Vehicle-controlled Phase 2 Study of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis Stratifying Risk for Early Onset Atopic Dermatitis from Birth: An Artificial Intelligence Empowered Clinical Decision Support Tool |
| 06.30 pm – 09.00 pm | Reception & poster viewing |
| THURSDAY, NOVEMBER 4, 2021 |
|
08.15 am – 8.45 am |
Chairs – Morning Session: Brian Brown (New York, NY, USA), Miriam Merad (New York, NY, USA) Developmental programs in inflammatory skin disease |
| 08.45 am – 09.15 am | Resident memory T cells in human health and disease Rachael Clark (Boston, MA, USA) |
| 09.15 am – 09.45 am | Regulatory T cells in Skin Michael Rosenblum (San Francisco, CA, USA) |
| 09.45 am – 10.30 am | Oral presentations from selected abstracts (non-CME)
Single-cell analysis unravels lineage plasticity of innate lymphoid cells in atopic dermatitis Commensal microbiome regulates epidermal barrier function and repair of the skin by signaling through the aryl hydrocarbon receptor Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis from infancy to adulthood |
| 10.30 am – 11.00 am | COFFEE BREAK |
| 11.00 am – 12.30 pm | Sponsored Lunch Symposium (Non-CME) supported by Sanofi Genzyme and Regeneron |
| 12.30 pm – 12.45 pm | COFFEE BREAK |
| 12.45 pm – 02.15 pm | Sponsored Lunch Symposium (Non-CME) supported by UCB – Union Chimique Belge |
| 02.15 pm – 02.30 pm | COFFEE BREAK |
| Chairs – Afternoon Session I: Amos Gilhar (Haifa, Israel) Emmilia Hodak (Tel Aviv, Israel)The 2.30pm-6.00pm segment is non-CME. |
|
| 02.30 pm – 03.00 pm | Novel developments in ichthyoses Amy S. Paller (Chicago, IL, USA) |
| 03.00 pm – 03.30 pm | Janus kinases in inflammation John O’Shea (Bethesda, MD, USA) |
| 03.30 pm – 04.00 pm | New therapeutic frontiers in atopic conditions George Yancopoulos (Tarrytown, NY, USA) |
| 04.00 pm – 04.30 pm | COFFEE BREAK |
| 04.30 pm – 05.00 pm | Chairs – Afternoon Session II: Alice Gottlieb (New York, NY, USA) Anne Bowcock (New York, NY, USA) Oral presentations from selected abstracts (non-CME) Deucravacitinib, a Selective TYK2 Inhibitor: Serum Markers of Psoriatic Disease Activity and Pharmacodynamic Responses From a Phase 2 Study Long-Term Efficacy of Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension Trial up to 172 Weeks IL-13 and IL-4 Promote Proliferation and mRNA Expression of MUC2 and MUC5AC in Primary Human Conjunctival Goblet Cells |
| 05.00 pm – 05.30 pm | Visualization of skin inflammation and resulting immunologic concepts Kenji Kabashima (Kyoto, Japan) |
| 05.30 pm – 06.00 pm | Oral presentations from selected abstracts (non-CME)
Spatial transcriptomics of Cutaneous and Systemic Lupus Erythematosus skin reveals insights into cell-cell communications, interferon skewing, and distinguishes clinical subtypes IL-23 maintains tissue resident memory Th17 cells in murine and psoriatic skin Treatment with KHK4083 (AMG 451), an antagonist of OX40, induces durable modulation of atopic dermatitis (AD) related blood/skin biomarkers |
| 06.00 pm – 07.30 pm | Sponsored Dinner Symposium (Non-CME) supported by Boehringer Ingelheim Pharma GmbH & Co. KG |
| 07.30 pm – 10.00 pm | Scientific Networking session |
| FRIDAY, NOVEMBER 5, 2021 |
| 08.00 am – 09.30 am | Sponsored Breakfast Symposium (Non-CME) supported by Incyte Corporation |
| 09.30 am – 09.45 am
|
COFFEE BREAK
Chairs – Morning Session: |
| 09.45 am – 10.15 am | How to perform successful clinical trials in inflammatory skin diseases Kristian Reich (Hamburg, Germany) |
| 10.15 am – 10.45 am | PSORT – New psoriasis frontiers Christopher Griffiths (Manchester, UK) |
| 10.45 am – 11.15 am | Hidradenitis and pustular psoriasis James G. Krueger (New York, NY USA) |
| 11.15 am – 11.45 am | Psoriasis – the translational path and access to drugs Mark Lebwohl (New York, NY, USA) |
| 11.45 am – 12.00 pm | COFFEE BREAK |
| 12.00 pm – 01.30 pm | Sponsored Lunch Symposium (Non-CME) supported by Janssen Immunology, Pharmaceutical Companies of Johnson & Johnson |
| 01.30 pm – 01.45 pm
|
COFFEE BREAK
Chairs – Afternoon Session I: |
| 01.45 pm – 02.15 pm | Atopic dermatitis Emma Guttman (New York, NY, USA) |
| 02.15 pm – 02.45 pm | Dermatomyositis Victoria P. Werth (Philadelphia, PA, USA) |
| 02.45 pm – 03.15 pm | Regulation of human T-Cell responses by ionic signals in the skin Christina Zielinski (Munich, Germany) |
| 03.15 pm – 03.45 pm | Oral presentations from selected abstracts (non-CME)
Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies Sphingosine 1-phosphate receptor signalling promotes hair growth and inhibits perifollicular T-cell expansion and immune privilege collapse ex vivo Netherton syndrome subtypes share IL-17/IL-36 signature with distinct type I IFN, Th2 and Th9 responses |
| 03.45 pm – 04.15 pm
|
COFFEE BREAK
Chairs – Afternoon Session II: |
| 04.15 pm – 04.45 pm | Translating Itch Neuroimmunology to New Therapies Brian Kim (St Louis, MO, USA) |
| 04.45 pm – 05.15 pm | Immune and neural network interactions Dan Kaplan (Pittsburgh, PA, USA) |
| 05.15 pm – 05.45 pm | The skin microbiome in wound healing and regeneration Elizabeth Grice (Philadelphia, PA, USA) |
| 05.45 pm – 06.15 pm | Microbiome and immune interactions early in life Tiffany Scharschmidt (San Francisco, CA, USA) |
| 06.15 pm – 06.45 pm | White adipose tissue and its role in innate host defense Richard Gallo (San Diego, CA, USA) |
| 06.45 pm – 07.00 pm | COFFEE BREAK |
| 07.00 pm – 08.30 pm | Sponsored Dinner Symposium (Non-CME) supported by Sanofi Genzyme and Regeneron |
| SATURDAY, NOVEMBER 6, 2021 |
| 08.00 am – 09.30 am | Sponsored Breakfast Symposium (Non-CME) supported by Eli Lilly and Company |
| 09.30 am – 09:45 am
|
COFFEE BREAK
Chairs – Morning Session: |
| 09.45 am – 10.15 am | Artificial Intelligence in dermatology Harald Kittler (Vienna, Austria) |
| 10.15 am – 10.45 am | Alopecia areata Angela Christiano (New York, NY, USA) |
| 10.45 am – 11.15 am | Acne: a disorder of lipid metabolism Robert Modlin (Los Angeles, CA, USA) |
| 11.15 am – 11.45 am | Vitiligo John Harris (Worcester, MA, USA) |
| 11.45 pm – 12.15 pm | Inflammation and cancer Thomas S. Kupper (Boston, MA, USA) |
| 12.15 pm – 12.30 pm | COFFEE BREAK |
| 12.30 pm – 02.00 pm | Sponsored Lunch Symposium (Non-CME) supported by LEO Pharma |
| 02.00 pm – 03.00 pm | Chairs – Afternoon Session: Saakshi Khattri (New York, NY, USA) Maryanne Makredes Senna (Boston, MA, USA) Oral presentations from selected abstracts (non-CME) EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with tralokinumab Histopathological Analysis of ECZTRA 1 Study Revealed the Reduction of Innate Lymphoid Cells in Skin of Atopic Dermatitis Patients After Tralokinumab Treatment Long-term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis Correcting immunological misfiring in obesity restores efficacy of targeted biologic therapy for inflammatory skin disease |
| 03.00 pm – 03.30 pm | Lupus Virginia Pascual (New York, NY, USA) |
| 03.30 pm – 04.00 pm | Sarcoidosis & Granulomatous diseases Misha Rosenbach (Philadelphia, PA, USA) |
| 04.00 pm – 04.30 pm | Oral presentations from selected abstracts (non-CME)
Modulation of serum biomarkers from PsO patients treated with risankizumab or ustekinumab in a Phase 3 study Sensory ganglia reprogram in response to cutaneous inflammation |
| 04.30 pm – 06.00 pm | Sponsored Dinner Symposium (Non-CME) supported by AbbVie |
| 06.00 pm | Closing & Farewell |